Drugs / mRNA-3210
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06147856 | Mar 2024 → Aug 2026 | phenylketonuria | ModernaTX, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-09-13 | ModernaTX, Inc. | Regulatory Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease q4web.com ↗
The Company has opened an Investigational New Drug Application (IND) for mRNA-3210. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-09-13 | ModernaTX, Inc. | Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease q4web.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-3210 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06147856 ↗ |
| Route | Intravenous | “IV infusion” NCT06147856 ↗ |